treatment of asthma

fevipiprant (inn; code name qaw039) is a drug being developed by novartis which acts as a selective, orally available antagonist of the prostaglandin d2 receptor 2 (dp2 or crth2).

as of 2016, it is in phase iii clinical trials for the treatment of asthma.

on monday, december 16, 2019, switzerland-based novartis officially announced that it was jettisoning fevipiprant from its development program, given that the medicine has failed in two additional clinical trials in patients with moderate-to-severe asthma. the firm said that it had hoped fevipiprant would be a billion-dollar-selling asthma drug.

we are api raw material vender of 872365-14-5 from china.

https://www.tcsindustry.com/pro/fevipiprant_hair_loss_fevipiprant_powder_fevipiprant_copd_research_buy_fevipiprant.html